Abscint's patented technology paves the way for personalized diagnosis and therapy.
Abscint, a VUB spin-off, has recently been granted a notice of allowance from the United States Patent and Trademark Office (USPTO) for its patent application. The patent, titled ‘Radio-labelled antibody fragments for use in the prognosis and diagnosis of cancer as for the prediction of cancer therapy response,’ is a significant achievement for Abscint, as it strengthens their intellectual property rights and enhances their commercial opportunities.
Abscint's innovative technology platform relies on single-domain antibodies, allowing for efficient targeting of specific molecular markers that can be visualized throughout the body via a quick scan. By utilizing this technology, Abscint aims to assist doctors and patients in identifying the most suitable treatment options for each unique case. This technology was developed by the collaborative efforts of Prof. Dr. Tony Lahoutte and Prof. Dr. Jo Van Ginderachter's research teams at VUB and VIB in Brussels.
This patent allows Abscint to better characterize tumours and select the most appropriate therapy, ultimately increasing the likelihood of complete remission. Through molecular imaging, Abscint's goal is to guide patients and doctors towards the proper treatment at the right time, providing a crucial step forward in the fight against cancer.
Click here to learn more about this patent.